Category

Archives

TGF-beta/Smad

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors

160 views | Dec 19 2023

Compound 15r, a novel 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivative, demonstrated potent inhibition of the TGF-β type 1 receptor (ALK5), with favorable pharmacokinetic properties, superior bioavailability to LY-3200882, and significant efficacy in inhibiting tumor growth in a CT26 xenograft mouse model. [Read the Full Post]

Claudin-3 facilitates the progression and mediates the tumorigenic effects of TGF-β in glioblastoma multiforme

184 views | Dec 17 2023

The study demonstrates that upregulated Claudin-3 in glioblastoma multiforme stimulates tumor cell growth, promotes epithelial-mesenchymal transition, and enhances the tumorigenic effects of transforming growth factor-β, suggesting that specific inhibitors targeting Claudin-3 could represent a promising approach for treating this aggressive brain tumor. [Read the Full Post]

Cardiac RGS7 and RGS11 drive TGFβ1-dependent liver damage following chemotherapy exposure

95 views | Dec 14 2023

The research findings reveal that RGS7 controls the release of TGFβ1 from the heart, influencing the multiorgan damage caused by chemotherapy and emphasizing the importance of cardiokine signaling in this process. [Read the Full Post]

Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation

161 views | Dec 12 2023

In the LPS-induced acute lung injury model, CCN3 knockdown significantly attenuated inflammatory cytokine expression, reduced apoptosis in alveolar epithelial cells, and inhibited NF-κB activation, indicating its pivotal role in regulating lung inflammation and apoptosis via the TGF-β/p-Smad or NF-κB pathway. [Read the Full Post]

Regional regulatory harmonisation initiatives: Their potential contribution to the newly established African medicines agency

509 views | Nov 30 2023

The study highlights the foundational role of regional medicines regulatory harmonization programs, such as the African Medicines Regulatory Harmonisation (AMRH) and East African Community Medicines Regulatory Harmonisation (EAC-MRH) initiatives, in supporting the operationalization of the African Medicine Agency (AMA), emphasizing the importance of strong national regulatory authorities and increased ratification of the AMA Treaty for ensuring access to essential medical products and technologies for the African people. [Read the Full Post]

RBM15 silencing promotes ferroptosis by regulating the TGF-β/Smad2 pathway in lung cancer

265 views | Oct 22 2023

Silencing of RNA binding motif protein 15 (RBM15) promotes ferroptosis and inhibits lung cancer cell growth through the TGF-β/Smad2 pathway, offering potential therapeutic implications for lung cancer treatment. [Read the Full Post]

BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma

205 views | Oct 15 2023

The study indicates that targeting BMP9-ID1 signaling may serve as a promising therapeutic strategy for advanced hepatocellular carcinoma (HCC) by inhibiting angiogenesis. [Read the Full Post]

Ultrasound-triggered in situ gelation with ROS-controlled drug release for cartilage repair

140 views | Oct 05 2023

A novel ROS-responsive in situ nanocomposite hydrogel loaded with kartogenin (KGN) and bone marrow-derived stem cells (BMSCs) effectively promotes chondrogenic differentiation and improves cartilage regeneration, offering potential for efficient cartilage repair. [Read the Full Post]

TXNIP Suppresses the Osteochondrogenic Switch of Vascular Smooth Muscle Cells in Atherosclerosis

170 views | Sep 28 2023

TXNIP is identified as a novel regulator of atherosclerotic calcification by suppressing bone morphogenetic protein signaling and inhibiting the phenotypic transition of vascular smooth muscle cells towards an osteochondrogenic phenotype. [Read the Full Post]

Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells

162 views | Jul 28 2023

The study found that alantolactone (ALT) inhibited the proliferation and promoted apoptosis of oral squamous cell carcinoma (OSCC) cells by disrupting mitochondrial homeostasis and regulating dynamin-related protein 1 (Drp1), suggesting its potential as a therapeutic candidate for OSCC. [Read the Full Post]